Clinical trials: Progesterone Resistance
Estrogen Receptor Positive, Male Breast Carcinoma
Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen
This phase II trial studies how well giving lapatinib ditosylate together with tamoxifen citrate works in treating patients with breast cancer that has spread from where it started to nearby tissue or lymph nodes or to other…
- Conditions
- Estrogen Receptor Positive, Male Breast Carcinoma, Progesterone Receptor Positive, Recurrent Breast Carcinoma
- Trial name
- NCT00118157
- Testing
- Laboratory Biomarker Analysis, Lapatinib Ditosylate, Tamoxifen Citrate
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Threatened Abortion, Progesterone Resistance
Progesterone Supplementation in Threatened Abortion
To decide whether progesterone supplementation in threatened abortion is a sound practice.
- Trial name
- Prothreat (NCT03930212)
- Testing
- Progesterone
- Where
- Egypt
- Volunteers
- 190 people
- Sponsor
- Tanta University
Estrogen Receptor Positive, HER2/Neu Negative
Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer
This randomized phase II trial studies the side effects and how well fulvestrant and palbociclib with or without copanlisib work in treating patients with hormone receptor positive, HER2 negative, stage IV breast cancer.
- Conditions
- Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT03377101
- Testing
- Copanlisib, Fulvestrant, Laboratory Biomarker Analysis
- Sponsor
- National Cancer Institute (NCI)
Atypical Endometrial Hyperplasia, Progesterone Resistance
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients
To investigate the efficacy of Gonadotropin-releasing Hormone Agonist (GnRHa) plus letrozole in obese progestin-insensitive atypical endometrial hyperplasia (EAH) patients.
- Conditions
- Atypical Endometrial Hyperplasia, Progesterone Resistance, Obesity
- Trial name
- NCT06390904
- Testing
- GnRH antagonist, Letrozole 2.5mg
- Where
- 2 sites in China
- Volunteers
- 29 people
- Sponsor
- Xiaojun Chen
Solid Tumor, Solid Tumor, Adult
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolerated dose (MTD) and/or preliminary recommended dose for expansion (RDE) of…
- Conditions
- Solid Tumor, Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Tumor
- Trial name
- NCT06264921
- Testing
- NKT3447
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- NiKang Therapeutics, Inc.
Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer
A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)
This is a study evaluating the efficacy, safety, and pharmacokinetics of zilovertamab vedotin in participants with metastatic solid tumors including previously treated cancers of triple-negative breast cancer (TNBC), non-TNBC…
- Conditions
- Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer, NSCLC, Estrogen-receptor-positive Breast Cancer
- Trial name
- NCT04504916
- Testing
- Zilovertamab vedotin
- Where
- 14 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Advanced Malignant Solid Neoplasm, Estrogen Receptor Positive
Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
This phase I trial studies the side effects and best dose of everolimus and trastuzumab when given together with letrozole in treating patients with hormone receptor-positive and human epidermal growth factor (EGF) receptor 2…
- Conditions
- Advanced Malignant Solid Neoplasm, Estrogen Receptor Positive, HER2/Neu Positive, Postmenopausal
- Trial name
- NCT02152943
- Testing
- Everolimus, Laboratory Biomarker Analysis, Letrozole
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Endometriosis
Salivary microRNA in Endometriosis: Correlation With Response to Progestin Therapy
This study aims to analyze the salivary miRNA specific for patients diagnosed with endometriosis, specifically evaluating the miRNA profile of patients who respond versus those who do not respond to progestin therapy.
- Trial name
- ENDOmiRNA (NCT06414720)
- Testing
- Dienogest 2 MG
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- University of Udine
Endometriosis, Uterine Diseases
SIRT-1 Antagonism for Endometrial Receptivity
Progesterone resistance is mediated through epigenetic modification through SirT1 activation and is thought to contribute to infertility and progression of endometriosis.
- Conditions
- Endometriosis, Uterine Diseases, Endometrial Diseases, Infertility Unexplained
- Trial name
- SAFER (NCT04184323)
- Testing
- EX-527 (Selisistat)
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Acute Myeloid Leukemia, Brain Glioblastoma
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer.
- Conditions
- Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative, Extensive Stage Small Cell Lung Carcinoma
- Trial name
- NCT03154190
- Testing
- Best Practice, Laboratory Biomarker Analysis, Supportive Care
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- Stanford University
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative…
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer
- Trial name
- NCT00031681
- Testing
- 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Neoplasms, Endometrial Cancer
Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia
This is a single-center, randomized, open-label, controlled clinical trial evaluating whether adding orlistat to standard progestin therapy can improve treatment response in patients receiving fertility-sparing treatment for…
- Conditions
- Endometrial Neoplasms, Endometrial Cancer, Atypical Endometrial Hyperplasia, Progestin Resistance
- Trial name
- PKUPH-ORLPP-EC (NCT07714070)
- Testing
- Orlistat, Progestin
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Peking University People's Hospital
Estrogen Receptor-positive Breast Cancer, Progesterone Receptor Positive Tumor
Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer
RATIONALE: Estrogen can cause the growth of tumor cells. Hormone therapy using therapeutic estradiol may fight breast cancer by lowering the amount of estrogen the body makes.
- Conditions
- Estrogen Receptor-positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Cancer, Stage IIIC Breast Cancer
- Trial name
- NCT01385280
- Testing
- therapeutic estradiol, exemestane, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Arizona
Breast Cancer, Stage II Breast Cancer
Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors
This phase II trial studies how well exemestane before surgery works in treating postmenopausal patients with newly diagnosed estrogen receptor positive stage II-III breast cancer.
- Conditions
- Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
- Trial name
- NCT01831076
- Testing
- Exemestane, Exemestane and tamoxifen
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Colorado, Denver
Progesterone Resistance
Variation of Progesterone in IVF Cycles
to examine if a natural daytime variation in progesterone levels may explain parts of the inconsistent findings from studies reporting divergent results concerning this matter and will be carried out by several blood samples from…
- Trial name
- NCT03519776
- Testing
- Progesterone variation
- Where
- United Arab Emirates
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- ART Fertility Clinics LLC
Endometrial Neoplasms, Atypical Endometrial Hyperplasia
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
To investigate the efficacy of GnRHa plus letrozole vs Diane-35 plus metformin in non-obese progestin-insensitive early-stage endometrial cancer (EEC) and atypical hyperplasia(EAH) patients asking for conservative treatment.
- Conditions
- Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance
- Trial name
- NCT05316935
- Testing
- GnRHa, Letrozole 2.5mg, Diane-35
- Where
- 2 sites in China
- Volunteers
- 80 people
- Sponsor
- Xiaojun Chen
Endometrial Neoplasms, Atypical Endometrial Hyperplasia
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
To investigate the efficacy of GnRHa plus letrozole in obese progestin-insensitive EEC patients.
- Conditions
- Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance, Obesity
- Trial name
- NCT06379113
- Testing
- GnRH antagonist, Letrozole 2.5mg
- Where
- 2 sites in China
- Volunteers
- 29 people
- Sponsor
- Xiaojun Chen
Solid Tumors, Advanced Cancer
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
The goal of this clinical research study to find the highest tolerated dose of anastrozole alone or in combination with either everolimus (Afinitor), sorafenib (Nexavar), erlotinib (Tarceva), fulvestrant (Faslodex), or…
- Trial name
- NCT01197170
- Testing
- Anastrozole, Bevacizumab, Everolimus
- Where
- United States
- Volunteers
- 277 people
- Sponsor
- M.D. Anderson Cancer Center
Endometriosis, Endometrial Diseases
Cancer Driving Mutations in Endometriosis Lesions and Development of Progesterone Resistance
This study will test the hypothesis that the molecular changes present in ectopic endometriosis lesions correlate with progesterone-resistant disease (using the criteria defined in this study) and are present in matched eutopic…
- Trial name
- NCT03756480
- Where
- 3 sites in United States
- Volunteers
- 135 people
- Sponsor
- Johns Hopkins University
Women's Health
Resistance Training and Sex Hormone Concentrations During the Menstrual Cycle
Although there are numerous studies showing effects of aerobic training on sex hormone concentrations, research analyzing the fluctuation of sex hormones in response to resistance training (RT) is lacking.
- Trial name
- NCT04163380
- Testing
- Resistance Training
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Southern Illinois University Edwardsville